Benefits and risks of testosterone treatment for hypoactive sexual desire disorder in women: A critical review of studies published in the decades preceding and succeeding the advent of phosphodiesterase type 5 inhibitors

Clinics

Volumn 69, Issue 4, 2014, Pages 294-303

  Reis, Sandra Léa Bonfim ^a   Abdo, Carmita H N ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Aging; Physiological; Sexual dysfunction; Sexuality; Testosterone

Indexed keywords

ANDROGEN; PHOSPHODIESTERASE V INHIBITOR; TESTOSTERONE;

ADOLESCENT; ADULT; AGE; DRUG EFFECT; FEMALE; HUMAN; LIBIDO; MIDDLE AGED; PSYCHOSEXUAL DISORDER; REVIEW; RISK FACTOR; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; ANDROGENS; FEMALE; HUMANS; LIBIDO; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; RISK FACTORS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TESTOSTERONE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84898760450     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2014(04)11     Document Type: Review

References (73)

1. Traish AM, Feeley RJ, Guay AT. Testosterone therapy in women with gynecological and sexual disorders: a triumph of clinical endocrinology from 1938 to 2008. J Sex Med. 2009;6(2):334-51.
2. Meston CM, Frohlich PF. The neurobiology of sexual function. Arch Gen Psychiatry. 2000;57(11):1012-30, http://dx.doi.org/10.1001/archpsyc.57. 11.1012.
3. Caldwell JD. A sexual arousability model involving steroid effects at the plasma membrane. Neurosci Biobehav Rev. 2002;26(1):13-30, http://dx. doi.org/10.1016/S0149-7634(01)00035-5.
4. Tillmann HC, Krüger UH, Manfred S. Prolactinergic and dopaminergic mechanisms underlying sexual arousal and orgasm in humans. World J Urolol. 2005;23:130-8.
5. Musicki B, Liu T, Lagoda GA, Bivalacqua TJ, Strong TD, Burnett AL. Endothelial nitric oxide synthase regulation in female genital tract structures. J Sex Med. 2009;Suppl 3:247-53.
6. Sato S, Braham CS, Putnam SK, Hull EM. Neuronal nitric oxide synthase and gonadal steroid interaction in the MPOA of male rats: co-localization and testosterone-induced restoration of copulation and nNOS immunoreactivity. Brain Res. 2005;1043(1-2):205-13, http://dx.doi.org/10. 1016/j.brainres.2005.02.074.
7. Traish AM, Kim NN, Munarriz R, Moreland R, Goldstein I. Biochemical and physiological mechanisms of female genital sexual arousal. Arch Sex Behav. 2002;31(5):393-400, http://dx.doi.org/10.1023/A:1019831906508.
8. Rowland DL. Neurobiology of sexual response in men and women. CNS Spectr. 2006;11(9):6-12.
9. Halaris A. Neurochemical aspects of the sexual response cycle. CNS Spectr. 2003;8(3):211-6.
10. Bancroft J. The endocrinology of sexual arousal. J Endocrinol. 2005; 186(3):411-27, http://dx.doi.org/10.1677/joe.1.06233.
11. West SL, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of Low Sexual Desire and Hypoactive Sexual Desire Disorder in a Nationally Representative Sample of US Women. Arch Intern Med. 2008;168(13):1441-9, http://dx.doi.org/10.1001/archinte.168.13.1441.
12. Abdo C. Descobrimento sexual do Brasil. São Paulo: Summus, 2004.
13. Dennerstein L, Koochaki PE, Barton I, Graziottin A. Hypoactive sexual desire disorder in menopausal women: a survey of Western European women. J Sex Med. 2006;3(2):212-22.
14. Santoro N, Torrens J, Crawford S, Allsworth JE, Finkelstein JS, Gold EB, Korenman S, et al. Correlates of circulating androgens in mid-life women: the study of women's health across the nation. J Clin Endocrinol Metab. 2005;90(8):4836-45, http://dx.doi.org/10.1210/jc.2004-2063.
15. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA. 2005;294(1):91-6, http:// dx.doi.org/10.1001/jama.294.1.91.
16. Schwenkhagen A, Studd J. Role of testosterone in the treatment of hypoactive sexual desire disorder. Maturitas. 2009;63(2):152-9, http:// dx.doi.org/10.1016/j.maturitas.2009.02.011.
17. Avis NE, Zhao X, Johannes CB, Ory M, Brockwell S, Greendale GA. Correlates of sexual function among multi-ethnic middle-aged women: results from the Study of Women's Health Across the Nation (SWAN). Menopause. 2005;2(4):385-98, http://dx.doi.org/10.1097/01.GME. 0000151656.92317.A9.
18. Schwenkhagen A. Hormonal changes in menopause and implications on sexual health. J Sex Med. 2007;4(3):220-6.
19. Basson R. Clinical practice. Sexual desire and arousal disorders in women. N. Engl J Med. 2006;354(14):1497-506.
20. Sarrel PM. Sexuality and menopause. Obstet Gynecol. 1990;75(4):26S-30S; discussion 31S-35S.
21. Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L, et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril. 2002;77(4):660-5, http://dx.doi.org/10.1016/S0015-0282(02)02969-2.
22. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W, et al. Androgen Therapy in Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2006;91(10):3697-710, http://dx.doi. org/10.1210/jc.2006-1121.
23. Traish A, Guay AT, Spark RF. Are the Endocrine Society's Clinical Practice Guidelines on Androgen Therapy in Women misguided? A commentary. J Sex Med. 2007;4(5):1223-34.
24. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab. 2005;90(7):3847-53, http://dx.doi.org/10.1210/jc. 2005-0212.
25. Guay A, Munarriz R, Jacobson J, Talakoub L, Traish A, Quirk F, et al. Serum androgen levels in healthy premenopausal women with and without sexual dysfunction: Part A. Serum androgen levels in women aged 20-49 years with no complaints of sexual dysfunction. Int J Impot Res. 2004;16(2):112-20.
26. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab. 2005;90(9):5226-33, http://dx.doi.org/10.1210/jc. 2004-1747.
27. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol. 2005;105(5 Pt 1):944-52, http://dx.doi.org/10.1097/01.AOG.0000158103.27672.0d.
28. Davis SR, van der Mooren MJ, van Lunsen RH, Lopes P, Ribot C, Rees M, et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause. 2006;13(3):387-96, http://dx.doi.org/10.1097/01.gme.0000179049.08371.c7.
29. Braunstein GD. Management of Female Sexual Dysfunction in Postmenopausal Women by Testosterone Administration: Safety Issues and Controversies. J Sex Med. 2007;4:859-66.
30. Kotsopoulos J, Narod SA. Androgens and breast cancer. Steroids. 2012;77:1-9, http://dx.doi.org/10.1016/j.steroids.2011.10.002.
31. Dimitrakakis C. Androgens and breast cancer in men and women. Endocrinol Metab Clin North Am. 2011;40(3):533-47, viii, http://dx.doi. org/10.1016/j.ecl.2011.05.007.
32. von Schoultz B. Androgens and the breast. Maturitas. 2007;57(1):47-9, http://dx.doi.org/10.1016/j.maturitas.2007.02.012.
33. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev. 2002;23(2):175-200, http://dx.doi.org/10.1210/edrv. 23.2.0460.
34. Mukherjee TK, Dinh H, Chaudhuri G, Nathan L. Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc Natl Acad Sci USA. 2002;99(6):4055-60, http://dx.doi.org/10. 1073/pnas.052703199.
35. Ling S, Dai A, Williams MR, Myles K, Dilley RJ, Komesaroff PA, et al. Testosterone (T) enhances apoptosis-related damage in human vascular endothelial cells. Endocrinology. 2002;143(3):1119-25, http://dx.doi.org/ 10.1210/endo.143.3.8679.
36. McCrohon JA, Death AK, Nakhla A, Jessup W, Handelsma DJ, Stanley KK, et al. Androgen receptor expression is greater in macrophages from male than from female donors. A sex difference with implications for atherosclerosis. Circulation. 2002;101(3):224-26.
37. Myers LS, Dixen J, Morrissette D, Carmichael M, Davidson JM. Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women. J Clin Endocrinol Metab. 1990;70(4):1124-31, http://dx.doi.org/10.1210/jcem-70-4-1124.
38. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas. 1995;21(3):227-36, http://dx.doi.org/10.1016/0378-5122(94) 00898-H.
39. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves wellbeing, mood, and sexual function in premenopausal women. Menopause. 2003;10:390-8, http://dx.doi.org/ 10.1097/01.GME.0000060256.03945.20.
40. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo controlled trial. Arch Intern Med. 2005;165(14): 1582-9, http://dx.doi.org/10.1001/archinte.165.14.1582.
41. Paula FJ, Soares JM Jr, Haidar MA, Lima GR, Baracat EC. The benefits of androgens combined with hormone replacement therapy regarding to patients with postmenopausal sexual symptoms. Maturitas. 2007;56(1): 69-77, http://dx.doi.org/10.1016/j.maturitas.2006.06.005.
42. Kingsberg S, Shifren J, Wekselman K, Rodenberg C, Koochaki P, Derogatis L. Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder. J Sex Med. 2007;4(4 Pt 1):1001-8.
43. El-Hage G, Eden JA, Manga RZA. A double-blind, randomized, placebocontrolled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. Climacteric. 2007;10(4):335-43, http://dx.doi.org/ 10.1080/13697130701364644.
44. Penteado SR, Fonseca AM, Bagnoli VR, Abdo CH, Júnior JM, Baracat EC. Effects of the addition of methyltestosterone to combined hormone therapy with estrogens and progestogens on sexual energy and on orgasm in postmenopausal women. Climacteric. 2008;11(1):17-25, http://dx.doi.org/10.1080/13697130701741932.
45. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000;343(10):682-8.
46. Louie KD. Transdermal testosterone replacement to improve women's sexual functioning. Can Fam Physician. 2001;47:1571-3.
47. Dobs AS, Nguyen T, Pace C, Roberts CP. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. Journal of Clinical Endocrinology and Metabolism. 2002;87:1509-16, http://dx.doi.org/10.1210/jcem.87.4. 8362.
48. Lobo RA, Rosen RC, Yang HM, Block B, van der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril. 2003;(79): 1341-52, http://dx.doi.org/10.1016/S0015-0282(03)00358-3.
49. Floter A, Nathorst-Boos J, Carlstrom K, Schoultz B. Addition of testosterone to estrogen replacement in oophorectomized women: effects on sexuality and well-being, Climacteric. 2002;5(4):357-65.
50. Blümel JE, Del Pino M, Aprikian D, Vallejo S, Sarrá S, Castelo-Branco C. Effect of androgens combined with hormone therapy on quality of life in post-menopausal women with sexual dysfunction. Gynecol. Endocrinol. 2008;24(12):691-5.
51. Panay N, Al-Azzawi F, Bouchard C, Davis SR, Eden J, Lodhi I, et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric. 2010;13(2):121-31, http://dx.doi.org/10. 3109/13697131003675922.
52. White WB, Grady D, Giudice LC, Berry SM, Zborowski J, Snabes MC. A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder. Am Heart J. 2012;163(1):27-32, http://dx.doi.org/ 10.1016/j.ahj.2011.09.021.
53. Sarrel P, Dobay B, Wiita B. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen only therapy. J Reprod Med 1998;43:847-56.
54. Sherwin BB. Randomized clinical trials of combined estrogen-androgen preparations: effects on sexual functioning. Fertil Steril. 2002;77 Suppl 4:S49-54, http://dx.doi.org/10.1016/S0015-0282(02)03002-9.
55. Arlt W. Androgen Therapy in women. Euro J. Endocrinol. 2006;154(1):1-11, http://dx.doi.org/10.1530/eje.1.02062.
56. Davis SR, Papalia MA, Norman RJ, O'Neill S, Redelman M, Williamson M, et al. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Ann Intern Med. 2008;148(8):569-77, http://dx.doi.org/10.7326/0003-4819-148-8-200804150-00001.
57. Janssen I, Powell LH, Kazlauskaite R, Dugan SA. Testosterone and visceral fat in midlife women: the Study of Women's Health Across the Nation (SWAN) fat patterning study. Obesity (Silver Spring). 2010;18(3):604-10, http://dx.doi.org/10.1038/oby.2009.251.
58. Golden SH, Ding J, Szklo M, Schmidt MI, Duncan BB, Dobs A. Glucose and insulin components of the metabolic syndrome are associated with hyperandrogenism in postmenopausal women. The atherosclerosis risk in communities study. Am J Epidemiol. 2004;160(6):540-8.
59. Sutton-Tyrrell K, Wildman RP, Matthews KA, Chae C, Lasley BL, Brockwell S, et al. Sex hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation. 2005;111(10):1242-9, http://dx. doi.org/10.1161/01.CIR.0000157697.54255.CE.
60. Lellamo F, Volterrani M, Caminiti G, Karam R, Massaro R, Fini M, et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol. 2010;56(16):1310-6.
61. Leão LC, Durat MP, Silva DM, Bahia PR, Coeli CM, Farias MLF. Influence of methyltestosterone postmenopausal therapy on plasma lipids, inflammatory factors, glucose metabolism and visceral fat: a randomized study. Eur J Endocrinol. 2006;154(1):131-9.
62. Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri-and postmenopausal women. Cochrane Database Syst Rev. 2005;(4): CD004509.
63. Van Staa TP, Sprafka JM. Study of adverse outcomes in women using testosterone therapy. Maturitas 2009;62(1):76-80, http://dx.doi.org/10. 1016/j.maturitas.2008.11.001.
64. Hofling M, Hirschberg AL, Skoog L, Tani E, Hägerström T, von Schoultz B. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause. 2007;14(2):183-90, http://dx.doi.org/10.1097/01.gme.0000232033.92411.51.
65. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz G. A. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med. 2006;166 (14):1483-9, http:// dx.doi.org/10.1001/archinte.166.14.1483.
66. Ness RB, Albano JD, McTiernan A, Cauley JA. Influence of estrogen plus testosterone supplementation on breast cancer. Arch Intern Med. 2009;169(1):41-6, http://dx.doi.org/10.1001/archinternmed.2008.507.
67. Jick S S, Hagberg KW, Kaye JA, Jick H. Postmenopausal estrogencontaining hormone therapy and the risk of breast cancer. Obstet Gynecol. 2009;113(1):74-80.
68. Davis SR, Wolfe R, Farrugia H, Bell RJ. The incidence of invasive breast cancer among women prescribed testosterone for low libido. J Sex Med. 2009;6(7):1850-6.
69. Kenemans P, van der Mooren MJ. Androgens and breast cancer risk. Gynecol Endocrinol. 2012;28(1):46-9, http://dx.doi.org/10.3109/09513590. 2012.651925.
70. Braunstein GD. Management of female sexual dysfunction in postmenopausal women by testosterone administration: Safety Issues and Controversies. J Sex Med. 2007;4:859-66.
71. Davis SR. Therapy The clinical use of androgens in female sexual disorders. J Sex Marital Ther. 1998;24(3):153-63, http://dx.doi.org/10. 1080/00926239808404930.
72. Barrett-Connor E, Timmons C, Young R, Wiita B. Interim safety analysis of a two-year study comparing oral estrogen-androgen and conjugated estrogens in surgically menopausal women. J Womens Health. 1996;5: 593-602, http://dx.doi.org/10.1089/jwh.1996.5.593.
73. Lobo RA. Androgens in postmenopausal women: production, possible role, and replacement options. Obstet Gynecol Surv. 2001;56(6):361-76, http://dx.doi.org/10.1097/00006254-200106000-00022.